EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis

Emily C L Wong iD, Parambir S Dulai iD, John K Marshall, Vipul Jairath, Walter Reinisch iD, Neeraj Narula iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf267 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Emily C L Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Eosinophils, Eosinophilia, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear.

Objective

This post-hoc analysis of the LUCENT-1 trial evaluated trends in serum and histologic eosinophils as biomarkers for early response to mirikizumab induction therapy in UC.

Design

Data from LUCENT-1 (NCT03518086) were analyzed to assess serum eosinophil counts and histologic eosinophil presence at baseline and week 12. Clinical response, remission, and endoscopic improvement were defined by modified Mayo score criteria. Logistic regression models, adjusted for factors including steroid use, prior biologic failure, disease severity, and albumin levels, assessed associations between baseline eosinophil levels and treatment outcomes.

Results

Among 928 participants, 66.6% achieved clinical response. Responders had higher baseline serum eosinophils (0.23 × 109/L vs 0.19 × 109/L, P = .001) and showed greater reductions at week 12. Elevated baseline eosinophils (≥0.57 × 109/L) were associated with higher rates of clinical response (80% vs 65.7%, aOR: 2.31, P = .013), remission (33.3% vs 25.1%, aOR: 1.91, P = .044), and endoscopic improvement (46.7% vs 33.8%, aOR: 2.33, P = .003). Reductions in histologic eosinophils were also linked to improved outcomes, especially in those with moderate/marked baseline presence. Conclusions and Relevance Baseline eosinophil levels may predict response to mirikizumab and guide early treatment decisions. These findings support a potential role for eosinophils as biomarkers in UC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeEosinophilsEosinophiliaAntibodies, Monoclonal, HumanizedHumansFemaleMaleBiomarkersAdultMiddle AgedTreatment OutcomeLeukocyte CountSeverity of Illness IndexPrognosis

Stichwörter der Autor:innen

eosinophilsmirikizumabulcerative colitis

Substanzen

BiomarkersAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada.
  • Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, L8S 4K1, Canada.
  • Division of Gastroenterology, Northwestern University, Chicago, IL, 60611, United States.
  • Department of Medicine, Division of Gastroenterology, Western University, London, ON, N6A 3K7, Canada.
  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090, Vienna, Austria.

ORCID-Profile: Emily C L Wong, Parambir S Dulai, Walter Reinisch, Neeraj Narula

Zitieren

APA

Wong, E. C. L., Dulai, P. S., Marshall, J. K., Jairath, V., Reinisch, W., & Narula, N. (2025). Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf267

Vancouver

Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf267

BibTeX
@article{Wong2025,
  author = {Wong, Emily C L and Dulai, Parambir S and Marshall, John K and Jairath, Vipul and Reinisch, Walter and Narula, Neeraj},
  title = {Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf267}
}
Kostenlos starten →